BCRP和Ki-67与乳腺癌新辅助化疗疗效的关系  

Levels of BCRP and Ki-67 predict the efficacy of neoadjuvant chemotherapy in breast cancer

作　　者：张彦收[1] 唐甜甜[1] 周涛[1] 王新乐[1] 刘运江[1] 

机构地区：[1]河北医科大学第四医院乳腺中心,河北石家庄050011

出　　处：《现代肿瘤医学》2017年第16期2588-2591,共4页Journal of Modern Oncology

基　　金：河北省卫生厅医学科学研究重点课题计划(自筹经费)(编号:20160666)

摘　　要：目的:探讨乳腺癌组织中乳腺癌耐药蛋白(breast cancer resistance protein,BCRP)和Ki-67的表达与新辅助化疗疗效之间的关系。方法:回顾性分析我科2012年10月至2014年8月收治的Ⅱ-Ⅲ期乳腺癌新辅助化疗患者65例,采用免疫组化方法检测BCRP和Ki-67的表达,分析BCRP、Ki-67的表达水平与新辅助化疗疗效的关系。结果:原发性乳腺癌组织中BCRP的阳性表达率为67.7%。BCRP的表达水平与新辅助化疗后病理组织学反应有关,组织学显著反应组(病理反应4~5级)BCRP的表达水平明显低于非显著反应组(病理反应1~3级),差异有统计学意义(χ~2=12.77,P=0.001)。化疗前Ki-67高表达组临床缓解率明显高于低表达组(χ~2=17.72,P<0.00)。结论:联合检测乳腺癌组织中BCRP和Ki-67的表达水平对新辅助化疗疗效有一定的预测价值。Objective：To investigate whether the expression of BCRP and Ki-67 expression in breast cancer could predict the efficacy of neoadjuvant chemotherapy.Methods：This research retrospectively analyzed 65 patients, who were diagnosed as invasive ductal carcinomas in stage Ⅱ-Ⅲ admitted in the breast cancer center in our hospital and accepted NAC from October 2012 to Augest 2014.Immunohistochemical assay was used to detect the BCRP and Ki-67 protein levels of 65 breast cancer tissues obtained by core needle biopsy before neoadjuvant chemotherapy.The relationship of BCRP and Ki-67 expression with efficacy of neoadjuvant chemotherapy was statistically analyzed.Results：The positive expression rate of BCRP was 67.7% in patients with primary breast cancer.The expression of BCRP was associated with the pathological response after neoadjuvant chemotherapy.BCRP expression in group of major histological response（grade of 4~5） was significantly lower than that in group of non major histological response（grade of 1~3）（x2=12.77,P=0.001）.Patients with Ki-67 over-expression were more sensitive than those with lower-expression（x2=17.72,P〈0.00）.Conclusion：The protein levels of BCRP and Ki-67 showed predictive value of the efficacy of neoadjuvant chemotherapy.

关 键 词：乳腺癌 新辅助化疗 BCRP KI-67 

分 类 号：R737.9[医药卫生—肿瘤]